No Data
Haisco Pharmaceutical Group (002653.SZ): Received the clinical trial approval notice for the Innovative Drug HSK41959 tablets.
On March 26, Gelonghui reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary Shanghai Haisco Shengnuo Pharmaceutical Technology Co., Ltd. recently received the "Notice of Drug Clinical Trial Approval" issued by the National Medical Products Administration for HSK41959 tablets. HSK41959 is a self-developed oral, potent, and highly selective small molecule inhibitor intended for the treatment of advanced solid tumors. According to the regulations of the National Medical Products Administration on the announcement of the "Chemical Drug Registration Classification and Application Material Requirements" (No. 44 of 2020), this product falls under the category of Chemical Drug.
Haisco Pharmaceutical Group Co., Ltd. (SZSE:002653) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Haisco Pharmaceutical Group (002653.SZ): received the drug clinical trial approval notice for two new indications of the Innovative Drugs HSK44459 tablets.
On March 12, Gelonghui reported that Haisco Pharmaceutical Group (002653.SZ) announced that its subsidiary Shanghai Haisco Shenno Pharmaceutical Technology Co., Ltd. recently received the "Notice of Approval for Clinical Trial of Pharmaceuticals" issued by the National Medical Products Administration. After review, the clinical trial applications for the two new indications "HSK44459 tablets for psoriasis and atopic dermatitis" accepted in December 2024 meet the relevant requirements for pharmaceutical registration, and permission is granted to conduct clinical trials for this product. HSK44459 is a new drug developed independently by the company with independent intellectual property rights for the treatment of psoriasis and atopic dermatitis. The results of preclinical studies show sufficient evidence.
Haisco Pharmaceutical Group Clarifies No Financial Assistance in Share Issuance
Gelonghui Announcement Selection︱ Baiwei Storage: Net income for the year 2024 is 0.176 billion yuan, a year-on-year increase of 128.14%; Shanghai DragonNet Technology: No business cooperation with DeepSeek at present.
【Hot News】Shenzhen Gongjin Electronics (603118.SH): Lidar products are not the company's main Business, accounting for less than 1% of the company's revenue. Ningbo Henghe Precision Industry (300539.SZ): Not involved in humanoid robot Business. Shanghai DragonNet Technology (300245.SZ): No current Business cooperation with DeepSeek. Wuxi Boton Technology (300031.SZ): Recently engaged in friendly exchanges and technical discussions with Yushu Technology, exploring innovative applications and implementations of industrial robot technology. 【Project Investment】Guangdong Guanghua Sci-Tech (002741.SZ): Plans to invest in the construction of an annual output of 0.1 million tons of high-performance Lithium Battery materials project.
What Haisco Pharmaceutical Group Co., Ltd.'s (SZSE:002653) 26% Share Price Gain Is Not Telling You
